Skip to Content
Merck
CN
  • Congenital hypomyelinating neuropathy attributable to a de novo p.Asp61Asn mutation of the myelin protein zero gene.

Congenital hypomyelinating neuropathy attributable to a de novo p.Asp61Asn mutation of the myelin protein zero gene.

Pediatric neurology (2013-01-08)
Takahiro Yonekawa, Hirofumi Komaki, Yuko Saito, Hiroshi Takashima, Masayuki Sasaki
ABSTRACT

We describe a boy aged 2 years and 11 months with congenital hypomyelinating neuropathy attributable to a de novo heterozygous missense mutation of c.181 G>A (p.Asp61Asn) in the myelin protein zero gene. A nerve conduction study indicated markedly reduced motor conduction velocities in the upper and lower extremities. Stimuli of up to 50-100 mA were necessary for nerve activation, suggesting diseased nerves with greatly decreased excitability. A sural nerve biopsy revealed a marked loss of large myelinated fibers, the absence of myelin breakdown products, occasional basal lamina onion-bulb formations, and tomacula-like structures. The p.Asp61Asn mutation is novel in congenital hypomyelinating neuropathy, but was previously reported in a patient with Charcot-Marie-Tooth disease type 1.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Asparagine, ≥98% (HPLC)
Sigma-Aldrich
L-Asparagine, BioReagent, suitable for cell culture, suitable for insect cell culture
Supelco
L-Asparagine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland